N/A N=60 Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program
Lung Diseases · Medication Compliance
Primary: Forced Oscillation Technique (FOT) Measures — 4.4; 3.7; 1.0; 0.6 resonant frequency
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 High-Intensity Interval Training to Improve Symptoms of Deployment-Related Respiratory Disease
Occupational Exposure
Primary: Maximum Oxygen Consumption (VO2max) — 26.4 ml/kg/min
N/A N=9 Woodsmoke Particulate + Hypertonic Saline
Airway Inflammation
Primary: Change From Baseline to 4 Hours in Sputum Percent Neutrophils — -0.04; -0.5 percent neutrophils — p=> 0.99
N/A N=15 Effects of the Breathe Technologies Ventilation System in Subjects With Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Primary: Exercise Duration for Constant Work Rate Exercise Tests Under 4 Test Conditions — 6.3; 17.5; 11.4; 5.6 minutes — p=<0.05
N/A N=58 The Development of a Human Model of Respiratory Syncytial Virus Infection
Respiratory Syncytial Virus Infections · Respiratory Viral Infections
Primary: Host Response to RSV Challenge Measured as Change From Baseline of Chemical Mediators in Nasal Fluid — 23 Participants
N/A N=26 Respiratory Impedance and Obliterative Bronchiolitis
Hematopoietic Stem Cell Transplantation · Obliterative Bronchiolitis
Primary: Airway Distensibility With Lung Inflation After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) — 0.07 1/cmH2O*s
Phase 3 N=122 GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs) — 120; 27 Participants
N/A N=59 Assessment of Airway Obstruction in Infants With Lower Respiratory Infections
Bronchiolitis · Respiratory Syncytial Virus Infections
Primary: Lung Function — 0.071; -3.179; 0.186; -3.345 Z score — p=0.0020
N/A N=50 Effects of Deployment Exposures on Cardiopulmonary and Autonomic Function
Abnormality, Respiratory System · Autonomic Nervous System
Primary: FEV1 — 0.94; 1.08; 0.95; 1.09 percentage of predicted normal values
N/A N=127 Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly
Respiratory Disorders
Primary: Mean Estimated Number of Acute Exacerbation of COPD (AECOPD) — 3.04 AECOPD/subject/year
N/A N=92 Respiratory Dysregulation and Breathing Training in Anxious Outpatients
Anxiety
Primary: Episodic Anxiety Scale — 8.1; 9.0; 14.3 units on a scale
Phase 2 N=12 Woodsmoke Particulate + Prednisone
Airway Inflammation
Primary: Change From Baseline to 4 Hours in Sputum Percent Neutrophils — -2.62; 5.45 percent neutrophils — p=0.24
N/A N=60 Health Effects of Diesel Exhaust in Asthmatic Patients: A Real-world Study in a London Street
Asthma
Primary: Spirometry, Percentage Change in FEV1 From Baseline — -1.0; -4.8; -2.2; -7.4 percentage change in FEV1 from baseline — p=<0.05
N/A N=1,283 Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of Breath
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With a Post-bronchodilator FEV1/FVC <=70% Versus Participants With a Postbronchodilator FEV1/FVC >70% — 308; 893 participants
N/A N=25 Respiratory Strength Training in Cardiac Surgical Patients
Cardiovascular Diseases · Thoracic Diseases · Surgery
Primary: Adherence to Respiratory Strength Training — 35750 Repetitions
N/A N=35 Molecular Breath Print of COPD Patients With Exacerbations Despite Triple Inhalational Therapy
COPD Exacerbation
Primary: Change in Exhaled Breath Metabolites — 3298 breath metabolites
N/A N=22 Non-invasive Ventilation System in Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive · Airflow Obstruction, Chronic · Chronic Obstructive Airway Disease
Primary: Device Tidal Volume — 180 mL
N/A N=1,333 Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
Pulmonary Arterial Hypertension
Primary: Prevalence of Respiratory Tract-Related Adverse Events of Interest — 52; 51; 16; 14 percentage of participants
Phase 3 N=1,024 A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly
Respiratory Tract Infections
Primary: Percentage of Subjects With Clinically Symptomatic Respiratory Illness — 125; 134 Participants
N/A N=29 Signs and Symptoms of Opioid-associated Iatrogenic Withdrawal in Critically Ill Adults
Substance Withdrawal Syndrome
Primary: Description of Signs and Symptoms of OIWS in Patients Who Scored Positive for Withdrawal Syndrome (OIWS) According to Diagnostic and Statistical Manual of Mental…
N/A N=55 External Nasal Dilator and Oxygen Therapy in Respiratory Failure
Acute Respiratory Failure
Primary: Change of Respiratory Status Using the Modified Bronchiolitis Severity Score, in Children Using External Nasal Dilators as an Adjuvant to High Flow Nasal Cannula Oxygen…
N/A N=41 Respiration Validation for CPM Device
Cardiopulmonary Disease
Primary: Accuracy of CPM System Calculated RR Versus Reference Device Via Percent of Error Accuracy of Respiration Rate — 99.1; 98.5 Percent
Early Phase 1 N=17 Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung
Healthy · Latent Tuberculosis Infection (LTBI)
Primary: Median Difference in CD4 Cell Response to Intrabronchial Instillation of Tuberculin Purified Protein Derivative (PPD) — 5.26; 0.725; 29.9; 2.92 % Antigen Specific T…
N/A N=24 The Effects of Respiratory Training on Voice
Muscle Tension Dysphonia
Primary: Post Training Lung Volume Initiation — 21.07; 27.04 % vital capacity relative to rest level — p=<0.0005
N/A N=272 Collection and Testing of Respiratory Samples
QIAGEN ResPlex II Advanced Panel · Influenza A · Respiratory Syncytial Virus Infections
Primary: Detection of Respiratory Viruses — 83 participants
N/A N=546 Inspiratory Strength and Respiratory Complications After SCI Injury
Spinal Cord Injuries · Pneumonia
Primary: Pneumonia — 70 Participants
N/A N=343 Respiratory Syncytial Virus (RSV) Follow-Up Study (MK-0476-374)
Respiratory Syncytial Virus Bronchiolitis
Primary: Percentage of Participants With Asthma at 6 Years of Age: Overall and by Prognostic Factor — 6.1; 11.2; 3.1; 9.6 percentage of participants
N/A N=152 Nasal and Bronchial Absorption Sampling in RSV Bronchiolitis
Bronchiolitis · Bronchiolitis, Viral · RSV Infection
Primary: The Number of Sampling Visits on Which Participants Are Willing to Undergo Nasosorption and/or NPA Sampling — 124; 60; 0; 0 Sampling visits
N/A N=34 RESP-FIT: Technology-Enhanced Self-Management in COPD
COPD
Primary: Intervention Feasibility (Number of Participants Who Adhered to Treatment) — 13; 14 Participants
Phase 2 N=44 Respiratory Kinematics of Cough in Healthy Older Adults and Parkinson's Disease
Cough · Parkinson's Disease
Primary: Peak Expiratory Flow Rate — 4.34; 3.92 Liters of air/second